EAACI Congress 2024
รายงานการพัฒนาล่าสุดในด้านโรคภูมิแพ้และภูมิคุ้มกันวิทยาทางคลินิกที่ EAACI Congress 2024 ในเมืองบาเลนเซีย ประเทศสเปน http://www.globenewswire.com/NewsRoom/AttachmentNg/d32f0dd2-5510-4922-aead-62719b31e294 บาเลนเซีย, สเปน, March 19, 2024 (GLOBE NEWSWIRE) -- European Academy of Allergy and Clinical Immunology...
EAACI Congress 2024
Conozca los últimos avances en Alergia e Inmunología Clínica en el Congreso EAACI 2024, Valencia, España https://www.globenewswire.com/NewsRoom/AttachmentNg/d32f0dd2-5510-4922-aead-62719b31e294 VALENCIA, España, March 19, 2024 (GLOBE NEWSWIRE) -- EAACI, Agencia Europea de Alergia e Inmunología...
EAACI Congress 2024
Meliputi Perkembangan Terkini Alergi dan Imunologi Klinikal di Kongres EAACI 2024 di Valencia, Sepanyol http://www.globenewswire.com/NewsRoom/AttachmentNg/d32f0dd2-5510-4922-aead-62719b31e294 VALENCIA, Sepanyol, March 19, 2024 (GLOBE NEWSWIRE) -- Akademi Alergi dan Imunologi Klinikal Eropah...
EAACI Congress 2024
アレルギーと臨床免疫学の最新動向を、スペイン、バレンシアで開催される「EAACI Congress 2024」で網羅 http://www.globenewswire.com/NewsRoom/AttachmentNg/d32f0dd2-5510-4922-aead-62719b31e294 スペイン、バレンシア発, March 19, 2024 (GLOBE NEWSWIRE) --...
EAACI Congress 2024
Couvrez les derniers développements en matière d'allergie et d'immunologie clinique lors du Congrès 2024 de l'EAACI à Valence en Espagne http://www.globenewswire.com/NewsRoom/AttachmentNg/d32f0dd2-5510-4922-aead-62719b31e294 VALENCE, Espagne, 19 mars 2024 (GLOBE NEWSWIRE) -- L'European Academy of Allergy and Clinical Immunology...
EAACI Congress 2024
Cover the Latest Developments in Allergy and Clinical Immunology at the EAACI Congress 2024 in Valencia, Spain https://www.globenewswire.com/NewsRoom/AttachmentNg/d32f0dd2-5510-4922-aead-62719b31e294 VALENCIA, Spain, March 19, 2024 (GLOBE NEWSWIRE) -- The European Academy of Allergy and Clinical...
Sema4_Logo2021_Primary_Gradient.png
Sema4 to Participate at Two Investor Conferences in June 2022
26 mai 2022 08h00 HE | Sema4
STAMFORD, Conn., May 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate...
Sema4_Logo2021_Primary_Gradient.png
Sema4 Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 mai 2022 16h05 HE | Sema4
STAMFORD, Conn., May 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that, effective as of May 2, 2022, the...
Sema4_Logo2021_Primary_Gradient.png
Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms
02 mai 2022 07h45 HE | Sema4
Acquisition creates an AI-driven advanced health intelligence company, now leveraging one of the largest genomic testing platforms in the U.S. Katherine Stueland, former President and CEO of GeneDx,...
Sema4_Logo2021_Primary_Gradient.png
Sema4 to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
26 avr. 2022 16h05 HE | Sema4
STAMFORD, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for...